Risk factors
CDT Equity (CDT) risk factors
Item 1A of every CDT Equity Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors38 risks3 dropped6 reworded
Accumulated deficit grew to $68.3 million and net loss widened to $39.2 million for fiscal 2025. Nasdaq delisting threats materialized with low bid price warnings.
Filed Apr 15, 2026 - FY2024 10-K risk factors41 risks
CDT Equity is an early-stage clinical biopharmaceutical company facing significant net losses and ongoing funding needs.
Filed Mar 28, 2025